John Tsai
Director/Board Member bij BLUEPRINT MEDICINES CORPORATION
Vermogen: 2 M $ op 29-02-2024
Profiel
Op dit moment is John Tsai Chief Medical Officer bij Novartis AG. In zijn vorige carrière was Dr. Tsai Chief Medical Officer & SVP-Global Medical bij Amgen, Inc. en Head-Clinical Development bij Bristol Myers Squibb Co. Hij behaalde een doctoraat aan de University of Louisville School of Medicine en een doctoraat aan de Washington University in St. Louis.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
NOVARTIS AG
0.00% | 31-12-2022 | 13 550 ( 0.00% ) | 1 M $ | 29-02-2024 |
21-06-2023 | 6 500 ( 0.01% ) | 607 880 $ | 29-02-2024 |
Actieve functies van John Tsai
Bedrijven | Functie | Begin |
---|---|---|
BLUEPRINT MEDICINES CORPORATION | Director/Board Member | 06-01-2023 |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Private Equity Investor | - |
Forcefield Therapeutics Ltd. | Chief Executive Officer | 27-09-2023 |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Chairman | 16-10-2023 |
Eerdere bekende functies van John Tsai
Bedrijven | Functie | Einde |
---|---|---|
NOVARTIS AG | Chief Tech/Sci/R&D Officer | 15-05-2022 |
AMGEN INC. | Chief Tech/Sci/R&D Officer | 01-01-2018 |
BRISTOL-MYERS SQUIBB COMPANY | Private Equity Investor | 01-01-2012 |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Director/Board Member | - |
Opleiding van John Tsai
Washington University in St. Louis | Undergraduate Degree |
University of Louisville School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
AMGEN INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
NOVARTIS AG | Health Technology |
BLUEPRINT MEDICINES CORPORATION | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
Forcefield Therapeutics Ltd. |